- Home
- PLRX vs AUTL Comparison
PLRX vs AUTL Comparison
Compare PLRX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | AUTL |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 596.2M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PLRX | AUTL |
|---|---|---|
| Price | $1.14 | $2.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $2.67 | ★ $8.50 |
| AVG Volume (30 Days) | 351.7K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | N/A | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $1.02 | $1.18 |
| 52 Week High | $1.95 | $2.58 |
Technical Indicators
Market Signals| Indicator | PLRX | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 46.33 |
| Support Level | $1.11 | $1.37 |
| Resistance Level | $1.21 | $2.07 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 56.52 | 27.78 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.